CoChat
Sign Up
Cited by 242Probiotics and Fermented FoodsEscherichia coli research studiesBacterial Genetics and Biotechnology

The DOI matches its Crossref record; 252 of the 252 references it cites were found in a registry or an index.

The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic

Open access
Sonnenborn, Ulrich, Schulze, Jürgen·2009·Microbial Ecology in Health and Disease
DOI 10.3109/08910600903444267
Open this paper in CoChat — free account

Abstract

Probiotics are non-pathogenic living microorganisms which, when administered in adequate amounts, confer a health benefit on the host. Probiotic microorganisms most often are constituents of special foodstuffs, such as fermented milk products or food supplements. They are also employed as feed additives in livestock breeding and as active components of medical remedies in human and veterinary medicine. In the food industry, probiotics traditionally are lactic acid bacteria (LAB), especially lactobacilli and lactococci, although bifidobacteria and strepcococci (enterococci) are also used. In livestock breeding and medicine, besides lactic acid bacteria other non-pathogenic microorganisms with health-promoting characteristics, e.g. certain strains of yeast (‘Saccharomyces boulardii’) and Escherichia coli (E. coli Nissle 1917), are also applied. This review focuses on the probiotic E. coli strain Nissle 1917 (EcN), its origin and medical history, microbiology, genetics, biological activities, safety, and toxicological aspects. Furthermore, clinical trials performed with this special E. coli strain will be summarized. The EcN strain was detected and isolated by Alfred Nissle in 1917 because of its antagonistic activity against some pathogenic entero-bacteria. With respect to its metabolic capacities, EcN is a typical E. coli strain. It is a non-pathogenic member of the Escherichia coli family, because it does does not carry pathogenic adhesion factors and does not produce any enterotoxins or cytotoxins, it is not invasive, not uropathogenic, and is rapidly killed by non-specific defense factors of blood serum. Besides this, EcN has some special characteristics that distinguish it from other pathogenic and non-pathogenic E. coli strains and are thought to be important for its probiotic activities. Thus, EcN carries so-called genomic islands (GEIs), integrated into its chromosome. On these GEIs, gene clusters coding for several fitness factors are present, e.g. genes for the production of microcins which inhibit the growth of other enterobacteria. Another strain-specific feature of EcN is a special lipopolysaccharide (LPS) in its outer cell membrane, being responsible for the fact that EcN exhibits immunomodulating properties without showing immunotoxic effects. The immunomodulating properties mainly focus on anti-inflammatory activities that are important for the clinical efficacy in remission maintenance of ulcerative colitis. Also of importance is the bacterial–epithelial crosstalk between EcN and the intestinal epithelial cells, leading to a strengthening of the epithelial barrier and the curing of ‘leaky gut’ phenomena. The restoration of a disturbed gut barrier by EcN is thought to be due to the stimulation of epithelial defensin production as well as to a ‘sealing effect’ on the tight junctions of the enterocytes. EcN has also been shown to induce the development of the gut immune system in animal models and human newborns. In addition, it has been found that products of EcN metabolism, probably acetic acid, promote colonic motility that might be helpful for therapeutic application in chronically constipated patients. Randomized controlled clinical trials (RCTs) have shown EcN to be therapeutically effective in rather diverse indications, such as ulcerative colitis, chronic constipation, and acute and protracted diarrhea.

Overview

Integrity signals

Registry

Crossref · 10.3109/08910600903444267

Cites

252 of 252 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 47

  1. Delcenserie V, 2008, Curr Issues Mol Biol, 10, 37
  2. Haenel H, 1975, Prog Food Nutr Sci, 1, 21
  3. Schulze J, Sonnenborn U, Ölschläger T, Kruis W. Probiotika - Mikroökologie, Mikrobiologie, Qualität, Sicherheit und gesundheitliche Effekte. Stuttgart: Hippokrates/Thieme. 2008.
  4. Sartor RB, 2005, Curr Opin Gastroenterol, 21, 44
  5. Tannock GW, 2003, Curr Issues Intest Microbiol, 4, 33
  6. Vergin F, 1954, Hippokrates, 25, 116
  7. Parker RB, 1974, Anim Nutr Health, 29, 4
  8. De Vrese M, 2008, Adv Biochem Eng Biotechnol, 111, 1
  9. Heselmans M, 2005, Curr Issues Intest Microbiol, 6, 1
  10. Nissle A, 1918, Med Klin, 2, 29
  11. Hamilton-Miller JMT, 2001, Infect Dis Rev, 3, 83
  12. Schmidt DS, 2009, Dissertation
  13. Sonnenborn U, 1991, Beziehungen zwischen Wirtsorganismus und Darmflora unter besonderer Berücksichtigung von Physiologie und Funktion der normalen Escherichia-coli-Flora
  14. Lorenz A, 1996, Microecol Ther, 24, 45
  15. Schulze J, 1992, Microb Ecol Health Dis, 5, iv
  16. Schröder H, 1992, Der Kinderarzt, 23, 1619
  17. Hockertz S, 1991, Arzneim-Forsch/Drug Res, 41, 1108
  18. Maeda K, 2004, Gastroenterology, 126, A-577
  19. Trebichavsky I, 1998, J Mol Med, 76, B-9
  20. Hockertz S, Arzneim-Forsch/Drug Res 1997;47(I), 793
  21. Clavel T, 2007, Curr Issues Intest Microbiol, 8, 25
  22. Schultz M, 2007, Int J Probiotics Prebiotics, 2, 85
  23. Cichon C, Gastroenterology, 2004, A-578
  24. Wehkamp J, 2002, Gastroenterology, 122, A75
  25. Konturek PC, 2007, Gastroenterology, 132, A-411
  26. Speit G, 2005, Methods Mol Biol, 291, 85
  27. Malchow H, 1995, Gastroenterology, 108, A-869
  28. Blum G, 1995, FEMS Microbiol Lett, 126, 189
  29. Sereny B, 1957, Acta Microbiol Hung, 4, 367
  30. Tröger H, 2003, Z Gastroenterol, 41, 771
  31. Frick JS, 2005, Int J Med Microbiol, 295, 131
  32. Oswald S, 1997, Dissertation
  33. Magistrelli C, 1992, Micro-biologica, 15, 397
  34. Smith HW, 1983, J Gen Microbiol, 129, 3121
  35. Plaßmann D, 2007, Eine retrospektive Untersuchung. Med Klin, 102, 888
  36. Matthes H, 2006, Gastroenterology, 130, A-119
  37. Malchow H, 1997, A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol, 25, 653
  38. Wurzel RM, 1999, Aktuel Dermatol, 25, 329
  39. Hibi T, 2003, J Gastroenterol, 38, 36
  40. Jones JL, 2006, Pract Gastroenterol, 30, 44
  41. Vogelsang H, 2003, Österreichische Ärztezeitung, 1, 40
  42. Bruckschen E, 1994, Münch Med Wochenschr, 16, 241
  43. Möllenbrink M, 1994, Med Klin, 89, 587
  44. Fuller R, 1992, Probiotics, 1
  45. Bendali F, 1999, Vet Res, 30, 509
  46. Drisko JA, 2003, Altern Med Rev, 8, 143
  47. Rao S, 2005, Proc Natl Acad Sci U S A, 102, 1993

Cited by

Sorted by citations

See all 242

Related

See all

Metadata

Authors
Sonnenborn, U., & Schulze, J.
Affiliations
  • Department of Biological Research
  • Ardeypharm (Germany) (DE)
Corresponding author
Sonnenborn, Ulrich
Venue
Microbial Ecology in Health and Disease
Publisher
Informa UK Limited
Published
2009-01
Volume
21
Issue
3-4
Pages
122-158
ISSN
  • 0891-060X (ISSN-L)
  • 1651-2235
DOI
10.3109/08910600903444267
OpenAlex
W1978437322
Cited by
232
References
252
Citations by year
2026: 20 · 2025: 20 · 2024: 19 · 2023: 13 · 2022: 20 · 2021: 28 · 2020: 14 · 2019: 23 · 2018: 17 · 2017: 9 · 2016: 14 · 2015: 8 · 2014: 10 · 2013: 6 · 2012: 5
FWCI
5.81
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
Microbial Ecology in Health and Disease (publishedVersion, cc-by)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
Keywords
Escherichia coli Nissle 1917, probiotics, genomic islands, lipopolysaccharide, immunomodulation, anti-inflammatory activity, ulcerative colitis, Crohn's disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review